Non-Interventional Study on Effectiveness of Elxaban Tab. in Patients With Non-valvular Atrial Fibrillation

• Conditions: Atrial Fibrillation

• Registration Number: NCT04125641
• Lead Sponsor: Yonsei University

Brief Summary

This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is patients with atrial fibrillation taking Elxaban (generic drug of apixaban) who visit hospital. The purpose is to analyze bleeding (major bleeding, minor bleeding), stroke, systemic embolism, death, other clinical events (acute myocardial infarction, pulmonary embolism, transient ischemic attack, hospitalization), drug adherence, questionnaire of life quality (AFEQT), cognitive function (KDSQ) according to the use of Elxaban.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-10-07
• Study First Submitted QC: 2019-10-11
• Study First Posted: 2019-10-14
• Status Verified: 2020-01
• Study Start: 2020-01-02
• Last Update Submitted: 2020-01-15
• Last Update Posted: 2020-01-18
• Primary Completion: 2022-08
• Study Completion: 2024-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

1. patients with atrial fibrillation taking Elxaban (patients with age more than 19)
2. Patients who agree with study inclusion

Exclusion Criteria

1. patients who do not agree with study inclusion
2. patients with age less than 19
3. Pregnancy, Breastfeeding

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
major bleeding	24 months	Major bleeding is defined according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH).; 1. Fatal bleeding, and/or; 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or; 3. Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.
death	24 months	Death included overall death, cardiovascular death and non-cardiovascular death.
systemic embolism	24 months	An SEE(systemic embolism) was defined by both clinical and objective evidence of sudden loss of end-organ perfusion
Stroke	24 months	Stroke included both ischemic and hemorrhagic stroke.

Secondary Outcome Measures

Name	Time	Method
cognitive function (KDSQ)	24 months	The KDSQ consists of three subscales (i.e., global memory function, other cognitive function, and instrumental activities of daily living), including 15 items that can detect early changes in cognitive decline to diagnose dementia.
other clinical events: acute myocardial infarction	24 months	Myocardial infarction (MI) is defined as a clinical (or pathologic) event in the setting of myocardial ischemia in which there is evidence of myocardial injury. The diagnosis is secured when there is a rise and/or fall of troponin (high sensitivity assays are preferred) along with supportive evidence in the form of typical symptoms, suggestive electrocardiographic (ECG) changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
other clinical events: pulmonary embolism	24 months	Pulmonary embolism is defined as sudden closure of a pulmonary artery or one of its branches, caused by a blood-borne clot or foreign material that plugs the vessel.
other clinical events: transient ischemic attack	24 months	Transient ischemic attack (TIA, Mini-Stroke) is defined as a neurological event with the signs and symptoms of a stroke, but which go away within a short period of time.
drug adherence	24 months	Drug adherence is defined as the extent to which a patient takes his or her medication as prescribed
questionnaire of life quality (AFEQT)	24 months	AFEQT is a validated questionnaire that was patient derived with expert clinical input, and is easy to use format with 20 questions on a seven point Likert scale. AFEQT evaluates Health Related Quality of Life (HRQoL) across three domains; * Symptoms - Four questions specifically targeted to assess AF related symptoms; * Daily Activities - Eight questions that evaluate daily function in AF patients; * Treatment Concerns - Six questions that assess AF treatment concerns in patients; * Scoring key provides information on how to score the questionnaire and explains how to interpret results. The scoring key provides the following scores:•Overall AFEQT Score (18 questions) •Treatment Satisfaction Score (2 questions)

Trial Locations

Locations (1)

Division of Cardiology Severance Cardiovascular Hospital, Yonsei University College of Medicine; 🇰🇷 Seoul, Korea, Republic of